A Phase 2 interventional study of RAD1901 and Placebo in Vasomotor Symptoms and Hot Flashes, sponsored by Radius Pharmaceuticals, Inc.. Terminated at 1 site in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-13.
Sponsored by Radius Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.
Among the 193 studies in Hot Flashes with a site in United States, this one is the 57th largest by enrollment of the 180 interventional ones that give a count, is one of 5 that started in 2015, is one of 41 in phase 2, and was the 121st registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+ · Men only
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
India Glycols Ltd · Sites in United States
Ages 45–60 · Women only
University of Kentucky · Sites in United States
Ages 18–99
University of Virginia · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 48 · Phase 3 40 · Phase 4 14
First in 1997; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 84 across the 180 interventional studies, 74 across the 6 observational. Of the 156 that completed or were terminated, 67 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 193 have an industry lead sponsor. The 10 most frequent:
Radius Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
Radius Pharmaceuticals, Inc. has 2 studies filed under Hot Flashes — fewer than ten, so there is no comparison to draw.
14 of the studies in Hot Flashes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07903480Primal Harvest, LLCA Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being | 2026-12 |
| NCT05193968Mayo ClinicHot Flashes and Neurovascular Function in Women | 2026-12 |
| NCT07861295Vidya USA CorporationSatavari and Ashoka for Menopause (SAM) Study | 2026-12-01 |
| NCT07335224Inova Health Care ServicesMen With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture | 2026-12-31 |
| NCT06972875University of VermontFezolinetant for Treating Hot Flashes in Men With Prostate Cancer | 2027-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 193 studies in Hot Flashes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to determine the clinical safety of RAD1901 and to evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor symptoms (VMS; "hot flashes") in postmenopausal women.
This was a Phase 2b outpatient, prospective, multicenter, double-blind, randomized, placebo-controlled study to determine whether elacestrant reduces the frequency and severity of vasomotor symptoms (VMS; "hot flashes") in postmenopausal women with moderate to severe hot flashes. Postmenopausal women who met study criteria were followed for 12 weeks on double-blind study medication and two weeks off study medication.
Treatment was randomized 1:1:1:1 to ensure that an approximately equal number of patients were exposed to each of three RAD1901 (elacestrant) doses (5, 10 and 20 mg/day) or placebo. The total period of placebo exposure was 14 weeks.
Enrolling approximately 300 patients was expected to provide power for testing superiority of the primary efficacy endpoint outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To have participated in this study, a subject MUST:
Exclusion Criteria:
Subjects with any of the following characteristics were not be eligible to participate in the study:
using any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RAD1901 5 mg/day
Drug: RAD1901
RAD1901 10 mg/day
Drug: RAD1901
RAD1901 20 mg/day
Drug: RAD1901
Placebo
Other: Placebo
RAD1901
Also known as: Elacestrant
Placebo
Change From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes
Change from baseline to week 12 in the average number of moderate and severe hot flashes per day, where change is calculated as week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency. Severity of hot flashes was self-assessed and reported as follows: * Mild: sensation of heat without sweating * Moderate: sensation of heat with sweating, able to continue activity * Severe: sensation of heat with sweating, causing cessation of activity.
Time frame: Baseline and 12 weeks
Change From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes
Change from baseline to week 4 in the average number of moderate and severe hot flashes per day, where change is calculated as week 4 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.
Time frame: Baseline and 4 weeks
Change From Baseline to Week 4 and Week 12 in the Severity of Hot Flashes
Change from baseline to week 4 and week 12 in the average daily severity of hot flashes, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash severity. Subjects recorded the number of hot flashes per day using an electronic diary. Daily severity score for hot flashes for each subject was calculated as the sum of the number of mild hot flashes, plus 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of mild, moderate, and severe hot flashes. That is, Daily Severity Score = (Fmild + 2•Fmod + 3•Fsev)/(Fmild + Fmod + Fsev) where Fmild= frequency of mild hot flashes, Fmod = frequency of moderate hot flashes, Fsev = frequency of severe hot flashes. The measure is a weighted average of the frequencies of Hot Flashes.
Time frame: Baseline, 4 weeks, and 12 weeks
Change From Baseline to Week 4 and Week 12 in the Frequency of All Hot Flashes
Change from baseline to week 4 and week 12 in the average number of all hot flashes (mild, moderate, and severe) by eDiary, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.
Time frame: Baseline, 4 weeks, and 12 weeks
| Milestone | Regimen 1 | Regimen 2 | Regimen 3 | Regimen 4 |
|---|---|---|---|---|
| Started | 38 | 34 | 29 | 38 |
| Completed | 37 | 32 | 26 | 33 |
| Not completed | 1 | 2 | 3 | 5 |
Change from baseline to week 12 in the average number of moderate and severe hot flashes per day, where change is calculated as week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency. Severity of hot flashes was self-assessed and reported as follows: * Mild: sensation of heat without sweating * Moderate: sensation of heat with sweating, able to continue activity * Severe: sensation of heat with sweating, causing cessation of activity.
| moderate to severe hot flashes per day | Regimen 1 | Regimen 2 | Regimen 3 | Regimen 4 |
|---|---|---|---|---|
| Change From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes | -3.48 ± 0.793 | -3.74 ± 0.867 | -4.12 ± 0.944 | -3.66 ± 0.808 |
Change from baseline to week 4 in the average number of moderate and severe hot flashes per day, where change is calculated as week 4 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.
| moderate to severe hot flashes per day | Regimen 1 RAD1901 5 mg | Regimen 2 RAD1901 10 mg | Regimen 3 RAD1901 20 mg | Regimen 4 Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes | -1.15 ± 3.644 | -2.22 ± 4.872 | -2.70 ± 3.764 | -3 ± 4.075 |
Change from baseline to week 4 and week 12 in the average daily severity of hot flashes, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash severity. Subjects recorded the number of hot flashes per day using an electronic diary. Daily severity score for hot flashes for each subject was calculated as the sum of the number of mild hot flashes, plus 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of mild, moderate, and severe hot flashes. That is, Daily Severity Score = (Fmild + 2•Fmod + 3•Fsev)/(Fmild + Fmod + Fsev) where Fmild= frequency of mild hot flashes, Fmod = frequency of moderate hot flashes, Fsev = frequency of severe hot flashes. The measure is a weighted average of the frequencies of Hot Flashes.
| hot flash severity score per day | Regimen 1 RAD1901 5 mg | Regimen 2 RAD1901 10 mg | Regimen 3 RAD1901 20 mg | Regimen 4 Placebo |
|---|---|---|---|---|
| Week 4 change from baseline in severity | -0.04 ± 0.25 | -0.07 ± 0.26 | -0.13 ± 0.273 | -0.00 ± 0.280 |
| Week 12 change from baseline in severity | -0.09 ± 0.337 | -0.08 ± 0.373 | -0.13 ± 0.313 | -0.01 ± 0.409 |
Change from baseline to week 4 and week 12 in the average number of all hot flashes (mild, moderate, and severe) by eDiary, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.
| hot flashes per day | Regimen 1 RAD1901 5 mg | Regimen 2 RAD1901 10 mg | Regimen 3 RAD1901 20 mg | Regimen 4 Placebo |
|---|---|---|---|---|
| Week 4 change from baseline | -0.99 ± 3.803 | -2.23 ± 4.792 | -2.29 ± 3.754 | -3.27 ± 4.107 |
| Week 12 change from baseline | -3.47 ± 5.076 | -2.40 ± 3.560 | -3.91 ± 5.263 | -3.74 ± 4.228 |
Collected over Up to 14 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regimen 1 RAD1901 5 mg | 0/38 (0%) | 0/38 (0%) | 11/38 (28.9%) |
| Regimen 2 RAD1901 10 mg | 0/34 (0%) | 0/34 (0%) | 3/34 (8.8%) |
| Regimen 3 RAD1901 20 mg | 0/29 (0%) | 0/29 (0%) | 7/29 (24.1%) |
| Regimen 4 Placebo | 0/38 (0%) | 0/38 (0%) | 13/38 (34.2%) |
| Event | Regimen 1 RAD1901 5 mg | Regimen 2 RAD1901 10 mg | Regimen 3 RAD1901 20 mg | Regimen 4 Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/38 | 0/34 | 0/29 | 4/38 |
| Vaginal haemorrhageReproductive system and breast disorders | 2/38 | 1/34 | 1/29 | 4/38 |
| DyspepsiaGastrointestinal disorders | 0/38 | 1/34 | 2/29 | 1/38 |
| Upper respiratory tract infectionInfections and infestations | 1/38 | 0/34 | 2/29 | 2/38 |
| DiarrhoeaGastrointestinal disorders | 1/38 | 0/34 | 1/29 | 2/38 |
| Abdominal PainGastrointestinal disorders | 0/38 | 1/34 | 0/29 | 2/38 |
| SinusitisInfections and infestations | 0/38 | 0/34 | 1/29 | 2/38 |
| HeadacheNervous system disorders | 2/38 | 1/34 | 1/29 | 2/38 |
| Back painMusculoskeletal and connective tissue disorders | 2/38 | 1/34 | 0/29 | 0/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/38 | 0/34 | 0/29 | 0/38 |
mITT population
| Age, Continuous(years) | Regimen 1 RAD1901 5 mg | Regimen 2 RAD1901 10 mg | Regimen 3 RAD1901 20 mg | Regimen 4 Placebo | Total |
|---|---|---|---|---|---|
| Mean | 56.6 ± 4.83 | 55.4 ± 5.08 | 54.1 ± 4.07 | 53.9 ± 5.09 | 55.1 ± 4.9 |
| Sex: Female, Male(Participants) | Regimen 1 RAD1901 5 mg | Regimen 2 RAD1901 10 mg | Regimen 3 RAD1901 20 mg | Regimen 4 Placebo | Total |
|---|---|---|---|---|---|
| Female | 38 | 34 | 28 | 38 | 138 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Regimen 1 RAD1901 5 mg | Regimen 2 RAD1901 10 mg | Regimen 3 RAD1901 20 mg | Regimen 4 Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 8 | 7 | 6 | 29 |
| Not Hispanic or Latino | 30 | 26 | 21 | 32 | 109 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Regimen 1 RAD1901 5 mg | Regimen 2 RAD1901 10 mg | Regimen 3 RAD1901 20 mg | Regimen 4 Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 1 | 3 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 12 | 6 | 10 | 34 |
| White | 30 | 22 | 21 | 27 | 100 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Regimen 1 RAD1901 5 mg | Regimen 2 RAD1901 10 mg | Regimen 3 RAD1901 20 mg | Regimen 4 Placebo | Total |
|---|---|---|---|---|---|
| United States | 38 | 34 | 28 | 38 | 138 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Dec 2015, a primary completion of Dec 2016 and a completion of May 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elacestrant
Radius Pharmaceuticals, Inc.